Analysis Tools
digestive/alimentary system
|
• at 4 months after inoculation with Helicobacter felis (H. felis), tamoxifen-treated mice develop significantly less Helicobacter-induced spasmolytic polypeptide-expressing metaplasia (SPEM) than 4-month-infected wild-type controls, as shown by reduced GSII-lectin staining and recovery of some H+, K+ -ATPase+ parietal cells
|
immune system
|
• H. felis-infected tamoxifen-treated mice show an increased population of CD8+ cytotoxic T cells in the stomach relative to infected wild-type controls
|
|
• H. felis-infected tamoxifen-treated mice show decreased gastric interleukin-1 alpha (IL1a) levels relative to infected controls
|
|
• H. felis-infected tamoxifen-treated mice show decreased gastric TNF levels relative to infected controls
|
|
• H. felis-infected tamoxifen-treated mice show attenuated Helicobacter-induced gastric metaplasia relative to infected wild-type controls
|
homeostasis/metabolism
|
• H. felis-infected tamoxifen-treated mice show decreased gastric interleukin-1 alpha (IL1a) levels relative to infected controls
|
|
• H. felis-infected tamoxifen-treated mice show decreased gastric TNF levels relative to infected controls
|
hematopoietic system
|
• H. felis-infected tamoxifen-treated mice show an increased population of CD8+ cytotoxic T cells in the stomach relative to infected wild-type controls
|
